BIOCARDIA, INC. (BCDA) Announces Clinical Trial Update
BIOCARDIA, INC. (BCDA) provided an update on its clinical development programs.
Clinical Development Highlights:
Drug Program: partnering, system
Collaboration: Pre-Submission Meeting
🔬 Clinical Development Pipeline (BIOCARDIA, INC.):
Product
Type
Development Stage
Therapeutic Area
Source
Sham Treatment
Drug
Approved
Refractory Angina
ClinicalTrials.gov
CardiAMP Cell Therapy System
Drug
Approved
Refractory Angina
ClinicalTrials.gov
Sham
Other
Phase PHASE3
Heart Failure, Systolic
ClinicalTrials.gov
Autologous cell therapy
Drug
Phase PHASE3
Heart Failure, Systolic
ClinicalTrials.gov
Diagnostic Catheterization
Other
Phase PHASE1
Heart Failure, Systolic
ClinicalTrials.gov
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)
Other
Phase PHASE1
Heart Failure, Systolic
ClinicalTrials.gov
intravenous delivery of allogeneic bone marrow-derived MSCs
Other
Phase PHASE1
ARDS, Human
ClinicalTrials.gov
Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
Drug
Approved
Ischemic Heart Failure
ClinicalTrials.gov
Transendocaridal Transplantation of Autologous Bone Marrow
📋 BIOCARDIA, INC. (BCDA) - Clinical Trial Update
Filing Date: 2026-05-08
Accepted: 2026-05-08 08:00:09
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (BIOCARDIA, INC.):
💼 Business Developments:
Structured Data: